ArticleCureus2026
p53 Immunohistochemistry Expression in Epithelial Ovarian Tumors.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Epithelial ovarian carcinoma usually has TP53 expression. The TP53 gene is the most frequently mutated gene in ovarian cancer and therapies targeting these mutations may improve treatment outcomes, but there are only few studies on p53 immunohistochemistry expression in ovarian tumors in India, leading to this study. Objective To study the expression of p53 mutation in epithelial ovarian carcinoma and to find its association with histological type, grade, and TNM staging. Methodology This is a laboratory-based explorative study. Expression of p53 was examined in 62 cases of epithelial ovarian carcinoma. Key parameters, including age, site of distribution, histological variant, tumor grade, and TNM stage, were analyzed for correlations with p53 expression using the chi-square test. Results Out of 62 cases studied, serous cystadenocarcinoma was the largest group, with 53 cases (85.5%), followed by mucinous cystadenocarcinoma with five cases (8%) and sero-mucinous cystadenocarcinoma with four cases (6.4%). 77.4% of serous cystadenocarcinoma cases (41/53) and all four cases of sero-mucinous cystadenocarcinoma (100%) showed 5+ staining, while none of the mucinous cystadenocarcinoma cases exhibited 5+ expression. p53 expression significantly correlated with histological variant of tumor (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.